Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07813039
PHASE1
A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation
Sponsor: Vertex Pharmaceuticals Incorporated
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the relative bioavailability of VX-581 tablet formulation compared to a suspension formulation along with its safety and tolerability.
Official title: A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Tablet Formulation of VX-581 in Healthy Adult Subjects
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-09-23
Completion Date
2026-10-27
Last Updated
2026-10-19
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
VX-581
Tablet and Suspension for Oral Administration.
Locations (1)
Celerion - Tempe
Tempe, Arizona, United States